Zymeworks ZYME
NASDAQ ZYME
$29.40 -0.50 (-1.66%)
As of: Sep 4, 2026 · 3:15 PM EDT

Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026)

Zymeworks (ZYME) posted Non-Current Deferred Tax Liability of $3.8 million for Q1 2026, down 36.51% sequentially from $6.0 million in Q4 2025, and down 20.52% YoY from $4.8 million in Q1 2025.

Analysis

Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends

Zymeworks has reported Non-Current Deferred Tax Liability for 6 years, with the latest figure at $3.8 million in Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability fell 20.52% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 20.52% YoY) and the FY2025 annual result came in at $6.0 million, down 35.91% from the prior year.
  • Non-Current Deferred Tax Liability slipped to $3.8 million in Q1 2026 per ZYME's latest filing, from $6.0 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $13.0 million in Q4 2023 and troughed at $1.6 million in Q3 2022.
  • A 5-year average of $4.4 million and a median of $3.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
  • The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability soared 627.63% in 2023, then tumbled 35.91% in 2025.
  • Over 5 years, Non-Current Deferred Tax Liability stood at $1.8 million in 2022, then jumped by 627.63% to $13.0 million in 2023, then declined by 27.7% to $9.4 million in 2024, then sank by 35.91% to $6.0 million in 2025, then slumped by 36.51% to $3.8 million in 2026.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.8 million, $6.0 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn -
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
10 Zymeworks 2.15 Bn 1.88 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.74 Mn
Mar 31, 2026 3.83 Mn
Dec 31, 2025 6.03 Mn
Sep 30, 2025 4.77 Mn
Jun 30, 2025 4.85 Mn
Mar 31, 2025 4.82 Mn
Dec 31, 2024 9.41 Mn
Sep 30, 2024 3.46 Mn
Jun 30, 2024 3.40 Mn
Mar 31, 2024 3.35 Mn
Dec 31, 2023 13.01 Mn
Sep 30, 2023 1.97 Mn
Jun 30, 2023 1.92 Mn
Mar 31, 2023 1.86 Mn
Dec 31, 2022 13.27 Mn
Sep 30, 2022 1.59 Mn
Dec 31, 2021 14.10 Mn